This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Powerful perspectives
![Giusy di Conza](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/05/Giusy-Di-Conza-1-819x1024.jpg)
Industry Insight
A bold new era in global cancer drug discovery
![Catherine Pickering](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Catherine-Pickering-1.jpg)
Industry Insight
A note from our CEO
![Giusy Di Conza Comp 2](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/07/Giusy-Di-Conza-comp-2.jpg)
Industry Insight
Realising the potential of autotaxin therapy in cancer
![Pexels Thirdman 7659470](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/pexels-thirdman-7659470-1.jpg)
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
![Michael Lahn 819x1024](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Michael-Lahn-819x1024-1.jpg)
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
![Press Releases Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Press-releases-bg.png)
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
![Press Releases Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Press-releases-bg.png)
€80 million Series B financing to progress pipeline through Phase II trials
![Data & Publications Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Data-publications-bg.png)
Roginolisib: an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3kδ) in patients with uveal melanoma and advanced cancers
![Press Releases Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Press-releases-bg.png)
US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy
![Data & Publications Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Data-publications-bg.png)
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
![Data & Publications Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Data-publications-bg.png)
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nabpaclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
![Data & Publications Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Data-publications-bg.png)
Preclinical activity of novel TGF beta receptor I kinase Inhibitors IOA-359 and IOA-360 for treatment of anemia in MDS/AML
![Data & Publications Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Data-publications-bg.png)
Novel PI3Kδ inhibitor roginolisib synergizes with the Bcl-2 inhibitor venetoclax in hematological malignancies
![Press Releases Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Press-releases-bg.png)
Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO immuno-oncology congress 2023
![Data & Publications Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Data-publications-bg.png)
Safety and clinical efficacy of roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase Inhibitor delta (PI3Kδ)
![Press Coverage Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Press-coverage-bg.png)
pharmaphorum — Uveal melanoma: a new generation of therapies offers hope for patients
![Press Coverage Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/06/Press-coverage-bg.png)
Immuno-Oncology Insights — Navigating the complexities of immunotherapy: unraveling novel targets & pathways
![Hero Bg](https://wp-ionctura-2024.s3.eu-west-2.amazonaws.com/media/2024/05/hero-bg.jpg)
Looking for media
resources?